share_log

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22

Wedbush維持Astria Therapeutics的跑贏大盤,將目標股價上調至22美元
Moomoo 24/7 ·  03/26 09:34

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $17 to $22.

Wedbush分析師勞拉·奇科維持Astria Therapeutics(納斯達克股票代碼:ATXS)的表現跑贏大盤,並將目標股價從17美元上調至22美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論